Prophylactic administration of the probiotic bacterial strain Pediococcus pentosaceus LI05 alleviated disease symptoms and reduced intestinal damage in a mouse model of chronic colitis induced by dextran sulfate sodium. In the experimental study, published in BMC Microbiology, researchers examined how preventative treatment with the bacterial strain, designated as PPLi, influenced clinical manifestations and histological changes across repeated cycles of chemically induced colonic inflammation. The investigators reported that introducing the probiotic prior to dextran sulfate sodium exposure and maintaining administration throughout repeated disease cycles significantly attenuated colitis-related injury. These therapeutic outcomes included a clear reduction in colitis symptoms, diminished intestinal permeability, and decreased intestinal fibrosis in the treated mice.
To clarify the underlying biological changes associated with this protective response, the research team measured serum cytokines, tissue signaling molecules, and endocrine factors in the experimental model. The administration of PPLi led to decreased expression of proinflammatory cytokines in the animals. In addition, the probiotic regimen increased levels of glucagon-like peptide-1, or GLP-1, both within colonic tissue and in laboratory-cultured L cells. Alongside the increased GLP-1 concentrations, the authors documented measurable changes in colonic cyclic adenosine monophosphate, or cAMP, levels, providing evidence of cellular and biochemical alterations linked to the attenuation of colonic inflammation.
The investigation also assessed gut microbial composition and host metabolic profiles to identify physiological shifts accompanying the probiotic intervention. The researchers determined that PPLi administration was associated with changes in fecal microbial composition and metabolic profiles in mice exposed to repeated dextran sulfate sodium cycles. Specifically, metabolic profiling revealed increased levels of short-chain fatty acids and elevated concentrations of L-glutamate. These microbial and metabolic modifications occurred alongside the observed reductions in tissue damage and inflammatory markers, detailing the complex biological environment influenced by the probiotic strain.
Inflammatory bowel disease is recognized as a chronic, relapsing inflammatory disorder, and probiotics are currently under active scientific investigation as potential adjunctive treatments. While the probiotic strain Pediococcus pentosaceus LI05 had previously demonstrated protective effects against colonic inflammation, its specific anti-inflammatory mechanisms have remained incompletely understood. The authors emphasized that the observed improvements—including reduced colitis symptoms, decreased fibrosis, lower permeability, and altered cytokine and metabolite levels—occurred under a strict prophylactic schedule started before colitis induction and continued across repeated cycles. The study concludes that these animal model and cell culture findings provide a foundation supporting further investigation into the protective effects of PPLi under a prophylactic regimen.
Subject of Research: Prophylactic probiotic effects on murine chronic colitis
Article Title: Protective effects of prophylactic Pediococcus pentosaceus LI05 administration in DSS-induced chronic colitis in mice
Article References: Bian, X., Yang, L., Wu, W., Shi, D., Fang, D., Li, Y., Wu, J., Xie, J., Wang, K., Wang, Q., & Li, L. (2026). Protective effects of prophylactic Pediococcus pentosaceus LI05 administration in DSS-induced chronic colitis in mice. BMC Microbiology. https://doi.org/10.1186/s12866-026-05893-w
Image Credits: AI Generated
DOI: 10.1186/s12866-026-05893-w
Keywords: Pediococcus pentosaceus, probiotics, chronic colitis, inflammatory bowel disease, GLP-1, intestinal fibrosis, short-chain fatty acids, microbiome, Protective, effects, prophylactic, Pediococcus
News Source: Drew Townsend. (November 10, 2026). Prophylactic Pediococcus pentosaceus LI05 Reduces Chronic Colitis Severity in Mice. Scienmag.



